Scriptaid, a novel histone deacetylase inhibitor, enhances the response of human tumor cells to radiation

International Journal of Molecular Medicine

Volumn 25, Issue 1, 2010, Pages 25-29

  Kuribayashi, Takeshi ^a   Ohara, Maki ^a   Sora, Sakura ^a   Kubota, Nobuo ^a  

^a IBARAKI PREFECTURAL UNIVERSITY OF HEALTH SCIENCES   (Japan)

Author keywords

H2AX; Histone deacetylase inhibitor; Ku80; Radiosensitization; Scriptaid

Indexed keywords

6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; CELL PROTEIN; KU ANTIGEN; PROTEIN KU80; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ARTICLE; CANCER RADIOTHERAPY; CELL KILLING; CELL SURVIVAL; COLONY FORMATION; CONTROLLED STUDY; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG POTENTIATION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RADIOSENSITIVITY; SQUAMOUS CELL CARCINOMA; TUMOR CELL; WESTERN BLOTTING;

ANTIGENS, NUCLEAR; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURVIVAL; DNA BREAKS, DOUBLE-STRANDED; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; HYDROXYLAMINES; QUINOLINES; RADIATION; RADIATION-SENSITIZING AGENTS;

EID: 70549088952     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000309     Document Type: Article

References (32)

1. Struhl K: Histone acetylation and transcriptional regulation mechanisms. Genes Dev 12: 599-606, 1998.
2. Cress WD and Seto E: Histone deacetylases, transcriptional control, and cancer. J Cell Physiol 184: 1-16, 2000.
3. Marks P, Rifkind RA, Richon VM, Breslow B, Miller T and Kelly WK: Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1: 194-202, 2001.
4. Xu WS, Parmigiani RB and Marks PA: Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26: 5541-5552, 2007.
5. Sugita K, Koizumi K and Yoshida H: Morphological reversion of sis-transformed NIH3T3 cells by trichostatin A. Cancer Res 52: 168-172, 1992.
6. Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA and Richon VM: Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60: 5165-5170, 2000.
7. Burgess A, Ruefli A, Beamish H, Warrener R, Saunders N, Johnstone R and Gabrielli B: Histone deacetylase inhibitors specifically nonproliferating tumor cells. Oncogene 23: 6693-6701, 2004.
8. Zhang XD, Gillespie SK, Borrow JM and Hersey P: The histone deacetylase inhibitor suberic bishhydroxamate regulates the expression of multiple apoptotic mediators of melanoma cells. Mol Cancer Ther 3: 425-435, 2004.
9. Xu W, Ngo L, Perez G, Dokmanovic M and Marks PA: Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc Natl Acad Sci USA 103: 15540-15545, 2006.
10. Donadelli M, Costanzo C, Beghelli S, Scupoli T, Dandrea M, Bonora A, Piacentini P, Budillon A, Caraglia M, Scarpa A and Palmieri M: Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. Biochim Biophys Acta 1773: 1095-1106, 2007.
11. Zhang Y, Jung M and Dritschilo A: Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors. Radiat Res 161: 667-674, 2004.
12. Camphausen K, Burgan W, Cerra M, Oswald KA, Trepel JB, Lee MJ and Tofilon PJ: Enhanced radiation-induced cell killing and prolongation of γH2AX foci expression by the histone deacetyylase inhibitor MS-275. Cancer Res 64: 316-321, 2004.
13. Arundel GM, Glicksman AS and Leith JT: Enhancement of radiation injury in human colon tumor cells by the maturational agent sodium butyrate (NaB). Radiat Res 104: 443-448, 1985.
14. Munshi A, Kurland JF, Nishikawa T, Tanaka T, Hobbs ML, Tucker SL, Ismail S, Stevens C and Meyn RE: Histone deacetylase inhibitors radiosensitizes human melanoma cells by suppressing DNA repair activity. Clin Cancer Res 11: 4912-4922, 2005.
15. Munshi A, Tanaka T, Hobbs ML, Tucker SL, Richon VM and Meyn RE: Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of γ-H2AX foci. Mol Cancer Ther 5: 1967-1974, 2006.
16. Banuelos CA, Banáth JP, MacPhail SH, Zhao J, Reitsema T and Olive PL: Radiosensitization by the histone deacetylase inhibitor PCI-24781. Clin Cancer Res 13: 6816-6826, 2007.
17. Sun GH, Sohn TA, Ryu B and Kern SE: A nobel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. Cancer Res 60: 3137-3142, 2000.
18. Keen JC, Yan L, Mack KM, Pettit C, Smith D, Sharma D and Davidson NE: A nobel histone deadetylase inhibitor, scriptaid, enhances expression of functional estrogen α(ER) in ER negative human breast cancer cells in combination with 5-aza-2′-deoxycytidine. Breast Cancer Res Treat 81: 177-186, 2003.
19. Takai N, Ueda T, Nishida M, Nasu K and Narahara H: A nobel deacetylase inhibitor, scriptaid, induces growth inhibition, cell cycle arrest, and apoptosis in human endometric cancer and ovarian cancer cells. Int J Mol Med 17: 323-329, 2006.
20. Machida H, Matsumoto Y, Shirai M and Kubota N: Geldanamycin, an inhibitor of Hsp90, sensitizes human tumor cells to radiation. Int J Radiat Biol 79: 973-980, 2003.
21. Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G, Ngo L, Holmgren A, Jiang X and Marks PA: Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 102: 673-678, 2005.
22. Girinsky T, Rubin L, Pignon JP, Chavaudra N, Gazeau J, Dubray B, Cosset JM, Socie G and Fertil B: Predictive value of in vitro radiosensitivity parameters in head and neck cancers and cervical carcinoma: preliminary correlations with local control and overall survival. Int J Radiat Oncol Biol Phys 25: 3-7, 1993.
23. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y and Carrier F: Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63: 7291-7300, 2003.
24. Dowdy SC, Jiang S, Zhou XC, Hou X, Jin F, Podratz KC and Jiang SW: Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Mol Cancer Ther 5: 2767-2776, 2006.
25. Rogakou EP, Pilch DR, Orr AH, Ivanova VS and Bonner WM: DNA double-stranded breraks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273: 5858-5868, 1998.
26. Tuteja R and Tuteja N: Ku autoantigen: a multifunctional DNA binding protein. Crit Rev Biochem Mol Biol 35: 1-33, 2000.
27. Taccioli GE, Gottlieb TM, Blunt T, Priestley A, Demengeot, J, Mizuta R, Lehmann AR, Alt FW, Jackson SP and Jeggo PA: Ku80: product of the XRCC5 gene and its role in DNA repair and V(D)J recombination. Science 265: 442-445, 1994.
28. Nussenzweig A, Sokol K, Burgman P, Li L and Li GC: Hypersensitivity of Ku80-deficient cell lien and mice to DNA damage: the effects of ionizing radiation on growth, survival, and development. Proc Natl Acad Sci USA 94: 13588-13590, 1997.
29. Wachsberger PR, Li WH, Guo M, Chen D, Cheong N, Ling CC, Li G and Iliakis G: Rejoining of DNA double strand breaks in Ku80-deficient mouse fibroblasts. Radiat Res 151: 398-497, 1999.
30. McKenna WG, Weiss MC, Endlich B, Ling CC, Bakanauskas VJ, Kelsten ML and Muschel RJ: Synergistic effect of the v-myc omcogene with H-ras on radioresistance. Cancer Res 50: 97-107, 1990.
31. Hermens AF and Bentvelzen PA: Influence of the H-ras oncogene on radiation response of a rat rhabdomyosarcoma cell line. Cancer Res 52: 3073-3082, 1992.
32. Chang IY, Youn CK, Kim HB, Kim MH, Cho HJ, Yoon Y, Lee YS, Chung MH and You HJ: Oncogenic H-ras up-regulates expression of Ku80 to protect cells from γ-ray irradiation in NIH3Ts cells. Cancer Res 65: 6811-6819, 2005.